StockData
biote Corp. logo

biote Corp. (BTMD) stock

BTMDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$1.06+0.03 (+3.40%)

Close on Nov 13, 2026Market cap $38.26MP/E –Yield –

Earnings

biote's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 10, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$43.30M
-9.8% on a year earlier
EPS, Q3 FY2026
$0.01
$0.22 a year earlier
Latest guidance
Issued
Nov 4, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of biote's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 10, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$43.30M-9.8%$0.01Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026during market hours$44.20M-9.6%-$0.23Release
Q1 FY2026ended Mar 31, 2026May 6, 2026during market hours$44.90M-8.4%$0.06Release
Q4 FY2025ended Dec 31, 2025Mar 11, 2026during market hours$46.40M-6.8%$0.06Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025during market hours$48.00M-6.6%$0.22Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025during market hours$48.90M-0.6%$0.10Release
Q1 FY2025ended Mar 31, 2025May 7, 2025during market hours$49.00M+4.7%$0.37Release
Q4 FY2024ended Dec 31, 2024Mar 12, 2025during market hours$49.80M+9.0%$0.10Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024during market hours$51.40M+12.7%$0.33Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours$49.20M-0.2%-$0.19Release
Q1 FY2024ended Mar 31, 2024May 7, 2024during market hours$46.80M+4.5%-$0.06Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

biote's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueFY2026$175.00M–NewNov 4, 2026
RevenueFY2026$175.00M$190.00MLoweredAug 5, 2026
Adjusted EBITDAnon-GAAPFY2026$25.00M–NewNov 4, 2026
Adjusted EBITDAnon-GAAPFY2026$25.00M$38.00MLoweredAug 5, 2026

Guidance vs results

The last range biote gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$190.00M$192.30MΣ4QAbove range

Guidance history

Every forecast biote put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026Adjusted EBITDAFY2026$25.00MNew
Nov 4, 2026RevenueFY2026$175.00MNew
Aug 5, 2026Adjusted EBITDAFY2026$25.00MLowered
Aug 5, 2026RevenueFY2026$175.00MLowered
May 6, 2026Adjusted EBITDAFY2026$38.00MReaffirmed
May 6, 2026RevenueFY2026$190.00MReaffirmed
Mar 11, 2026Adjusted EBITDAFY2026$38.00MNew
Mar 11, 2026RevenueFY2026$190.00MNew
Nov 5, 2025Adjusted EBITDAFY2025$50.00MNew
Nov 5, 2025RevenueFY2025$190.00MNew
Aug 6, 2025Adjusted EBITDAFY2025$50.00MLowered
Aug 6, 2025RevenueFY2025$190.00MLowered
May 7, 2025Adjusted EBITDAFY2025$59.00M – $64.00MReaffirmed
May 7, 2025Dietary supplements revenueFY2025+5% – +10%Raised
May 7, 2025Procedure revenueFY2025+2% – +4%Lowered
May 7, 2025RevenueFY2025$202.00M – $208.00MReaffirmed
Mar 12, 2025Adjusted EBITDAQ1 FY2025-5%New
Mar 12, 2025Adjusted EBITDAFY2025$59.00M – $64.00MNew
Mar 12, 2025Procedure revenueFY2025+2% – +4%New
Mar 12, 2025Dietary supplements revenueFY2025+5% – +10%Raised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases biote filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Update
  6. Results
  7. Results
  8. Results
  9. Update
  10. Results
  11. Update
  12. Results
  13. Update
  14. Results
  15. Results

See a number that looks wrong?